基于卡片的临床试验包容性代表实施操作框架设计
针对临床试验人群代表性不足且现有框架缺乏角色分工与阶段化工具的问题,作者通过范围综述、15个框架的比较矩阵分析、120分钟专家咨询会及5W1H结构,开发了模块化卡片式操作框架。该框架含9类包容性代表类别、349条实施策略及KPI目录,明确15个功能团队职责与分阶段工作流程;专家肯定其可用性,但需真实世界进一步验证。
要点
- 框架含9类包容性代表类别,其中7类针对试验层面设计,2类针对组织准备度。
- 提供可编辑核心卡、支持卡、349条实施策略库及KPI目录以追踪进展。
- 明确15个功能团队职责及从发现到生命周期管理、从规划到数据读出的分阶段行动。
核心结论
- 该卡片式操作框架将多样性代表、健康公平与包容原则转化为面向申办方的结构化可操作指导。
- 框架通过决策支持工具、角色专属授权和可测量KPI弥补长期存在的操作缺口。
- 框架尚需在真实世界环境中进一步验证。
研究设计与样本
- 四阶段方法学研究:结构化范围综述、比较矩阵分析、120分钟专家咨询会、5W1H结构开发。
- 比较矩阵分析评估了15个框架的操作完整性并识别差距。
- 专家咨询会代表来自监管、学术、患者倡导和制药领域。
主要发现
- 最终框架为模块化卡片式工具集,组织为9类包容性代表类别。
- 框架包含可编辑核心卡、支持卡、349条实施策略库和KPI目录。
- 框架将包容性代表相关职责分配给15个功能团队,并提供分步工作流程和决策问题路径。
- 专家反馈肯定框架的可用性、相关性和完整性,并提出适应性、数字工具整合和绩效指标扩展等改进方向。
关键数值与推荐
- 框架覆盖产品生命周期从发现到生命周期管理,以及临床试验阶段从规划到数据读出。
- 框架使用5W1H(什么、为什么、谁、何时、何地、如何)结构组织内容。
临床怎么用
- 作者认为该框架可支持制药公司及申办方在临床试验中加强真实世界患者的代表性。
- 作者指出框架帮助申办方满足监管和伦理期望。
局限性
- 原文指出该框架尚需在真实世界环境中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite growing recognition that trial populations should reflect the broad range of people who will receive therapies, implementation of representative enrollment remains inconsistent. Existing frameworks often lack role-specific guidance, phase-specific actions, and actionable tools to support sponsors-referring specifically to pharmaceutical companies-in embedding inclusive representation (IR) across the trial life cycle. To address these gaps, we developed a card-based operational framework (CBOF) that assigns clear responsibilities, aligns with regulatory expectations, and supports implementation at both the trial and organizational levels. METHODS: We conducted a four-phase methodological study to design the CBOF. First, a structured scoping review identified existing frameworks tackling diverse representation, health equity, and inclusion, as well as guidance documents. Second, we performed a comparative matrix-based analysis to assess operational completeness, surface gaps across 15 frameworks, and to develop the design brief of the developed framework. Third, we held a 120-min expert advisory board consultation with representatives from regulatory, academic, patient advocacy, and pharmaceutical domains to validate the design brief. Fourth, we developed the CBOF using a 5W1H (What, Why, Who, When, Where, How) structure to inform framework content and format. RESULTS: The resulting CBOF consists of a modular, card-based tool set organized across nine inclusive representation "IR" categories: seven focused on trial-level design and two on organizational readiness. It includes editable Core Cards to prompt IR planning, Support Cards to provide guidance and role clarification, a library of 349 implementation tactics, and a KPI catalogue to track progress. The framework specifies who is responsible, when and where actions should occur across the product life cycle (discovery through life cycle management) and the clinical trial stages (planning to read out), and how each activity can be executed. It assigns IR-related responsibilities to 15 functional teams and includes step-by-step workflows and decision-question pathways. Expert feedback affirmed the framework's usability, relevance, and completeness, while also informing improvements such as adaptability, integration of digital tools, and expanded guidance on performance metrics. CONCLUSIONS: This framework has been designed to support companies and sponsors, specifically referring to pharmaceutical companies interested in strengthening the representation of real-world patients in clinical trials. The CBOF translates diverse representation, health equity, and inclusion principles into structured, actionable guidance for clinical trial sponsors. It addresses longstanding operational gaps by combining decision-support tools, role-specific delegation, and measurable KPIs across development phases and trial stages. While further validation in real-world settings is needed, the framework represents a practical advancement in operationalizing inclusive trial design and supporting sponsors in meeting regulatory and ethical expectations.
引用
- Minetti M, Paleari Y, Mazzoli C, et al. Design of a card-based operational framework for the implementation of inclusive representation in clinical trials. Trials. 2026. PMID: 41731557. doi:10.1186/s13063-026-09566-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。